GC Wellbeing Partner Reports Successful Phase 3 Trial in China
A next-generation fat-dissolving drug candidate has reported positive results in a Phase 3 clinical trial in China, showing a significant reduction in submental fat after a single treatment cycle.GC Wellbeing said on Sept. 3 that its partner, biotech company Raziel Therapeutics, had secured topline
GC Wellbeing's partner, biotech firm Raziel Therapeutics, has announced the successful completion of a Phase 3 clinical trial in China for their localized fat-dissolving injectable, RZL-012. The drug candidate demonstrated a significant reduction in submental fat after a single treatment cycle, with the response rate more than 30 percentage points higher than the placebo group.
The treatment, which aims to irreversibly destroy targeted fat cells, showed favorable safety results, supporting its potential for commercialization. Fosun Pharma and Raziel plan to file a New Drug Application with China's National Medical Products Administration, and are also considering expanding the treatment's use to other body-contouring areas such as the abdomen and thighs.
GC Wellbeing, which holds exclusive domestic licensing rights to RZL-012, expects growing demand for GLP-1 obesity treatments to be accompanied by increased demand for body-contouring treatments after weight loss. The company sees China as a key region in the global medical aesthetics market and believes the positive trial results will signal future commercialization in Korea and the expansion of their obesity business.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
